These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. Djamin RS; Bafadhel M; Uzun S; Russell REK; Ermens AAM; Kerstens R; Aerts JGJV; Pavord ID; van der Eerden MM Respir Med; 2019; 154():27-33. PubMed ID: 31203097 [TBL] [Abstract][Full Text] [Related]
8. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Han MK; Tayob N; Murray S; Dransfield MT; Washko G; Scanlon PD; Criner GJ; Casaburi R; Connett J; Lazarus SC; Albert R; Woodruff P; Martinez FJ Am J Respir Crit Care Med; 2014 Jun; 189(12):1503-8. PubMed ID: 24779680 [TBL] [Abstract][Full Text] [Related]
9. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Ra SW; Sze MA; Lee EC; Tam S; Oh Y; Fishbane N; Criner GJ; Woodruff PG; Lazarus SC; Albert R; Connett JE; Han MK; Martinez FJ; Aaron SD; Reed RM; Man SFP; Sin DD; Respir Res; 2017 May; 18(1):109. PubMed ID: 28558695 [TBL] [Abstract][Full Text] [Related]
10. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Uzun S; Djamin RS; Kluytmans J; Van't Veer NE; Ermens AA; Pelle AJ; Mulder P; van der Eerden MM; Aerts J Trials; 2012 Jun; 13():82. PubMed ID: 22682323 [TBL] [Abstract][Full Text] [Related]
11. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Herath SC; Poole P Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145 [TBL] [Abstract][Full Text] [Related]
12. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease. Allinson JP; Vlies BH; Brill SE; Law M; Burnside G; Finney LJ; Alves-Moreira L; Donaldson GC; Calverley PMA; Walker PP; Wedzicha JA Am J Respir Crit Care Med; 2023 Sep; 208(5):549-558. PubMed ID: 37450935 [No Abstract] [Full Text] [Related]
16. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Bafadhel M; Peterson S; De Blas MA; Calverley PM; Rennard SI; Richter K; Fagerås M Lancet Respir Med; 2018 Feb; 6(2):117-126. PubMed ID: 29331313 [TBL] [Abstract][Full Text] [Related]
17. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464 [TBL] [Abstract][Full Text] [Related]
18. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Bélanger M; Couillard S; Courteau J; Larivée P; Poder TG; Carrier N; Girard K; Vézina FA; Vanasse A Int J Chron Obstruct Pulmon Dis; 2018; 13():3045-3054. PubMed ID: 30319252 [TBL] [Abstract][Full Text] [Related]
19. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508 [TBL] [Abstract][Full Text] [Related]
20. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]